Ocular Therapeutix

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OCUL and other ETFs, options, and stocks.

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC.

CEO

Pravin U. Dugel

CEOPravin U. Dugel

Employees

267

Employees267

Headquarters

Bedford, Massachusetts

HeadquartersBedford, Massachusetts

Founded

2006

Founded2006

Employees

267

Employees267

OCUL Key Statistics

Market cap

775.84M

Market cap775.84M

Price-Earnings ratio

-4.16

Price-Earnings ratio-4.16

Dividend yield

—

Dividend yield—

Average volume

2.69M

Average volume2.69M

High today

$5.93

High today$5.93

Low today

$4.98

Low today$4.98

Open price

$5.90

Open price$5.90

Volume

9.13M

Volume9.13M

52 Week high

$11.31

52 Week high$11.31

52 Week low

$2.00

52 Week low$2.00

OCUL News

TipRanks 1d

Ocular Therapeutix Announces New Leadership and Incentive Plan Expansion - TipRanks.com - TipRanks

Ocular Therapeutix (OCUL) has shared an announcement. Ocular Therapeutix, Inc. has appointed Pravin U. Dugel, M.D., as its new President and CEO, bringing his...

TipRanks 2d

Ocular Therapeutix announces results from Phase 1 data for AXPAXLI

Ocular Therapeutix announced positive topline results from the Phase 1 HELIOS study evaluating AXPAXLI versus a sham control in patients with moderately severe...

TipRanks 5d

Ocular Therapeutix appoints Dugel as President, CEO

Ocular Therapeutix announced that Executive Chairman, Pravin Dugel, MD, is assuming the roles of President and Chief Executive Officer, and that Antony Mattessi...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More OCUL News

Yahoo Finance 5d

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is ... - Yahoo Finance

Ocular Therapeutix, Inc. BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company comm...